psychotropic agents

1. Introduction: Why Formulation Matters in Psychiatry

Psychotropic drugs treat mental health conditions. To be effective, they must reach the brain. However, formulating them into medicines is incredibly challenging.

Key reasons formulation is critical:

  • High patient variability: Patients respond differently to the same dose.

  • Adherence: Psychiatric conditions often require long-term therapy. Taking a pill every day for years is hard, especially if side effects are unpleasant or the patient feels "better" and stops taking them.

  • Side effects: Formulation can sometimes reduce side effects (e.g., avoiding peak-trough fluctuations in the blood).

  • The Blood-Brain Barrier (BBB): The brain has a protective shield that keeps toxins out—but it also keeps most medicines out.

The Goal: To get the right drug to the brain, at a stable level, in a way the patient can manage.


2. The Major Classes of Psychotropic Drugs

  1. Antidepressants: SSRIs (Selective Serotonin Reuptake Inhibitors), SNRIs (Serotonin-Noradrenaline Reuptake Inhibitors), TCAs (Tricyclic Antidepressants), MAOIs (Monoamine Oxidase Inhibitors). They work by increasing neurotransmitters (serotonin, noradrenaline, dopamine) in the brain.

  2. Antipsychotics:

    • First-generation (typical): e.g., Haloperidol. Strong blockers of dopamine receptors (D2).

    • Second-generation (atypical): e.g., Risperidone, Olanzapine. Block both dopamine and serotonin receptors.

  3. Mood Stabilisers: Lithium, Valproate, Carbamazepine, Lamotrigine. Used in bipolar disorder to prevent extreme mood swings.

  4. Anxiolytics and Hypnotics: Benzodiazepines (e.g., Diazepam) and Z-drugs (e.g., Zopiclone). Used for anxiety and insomnia.

  5. ADHD Medicines: Stimulants (Methylphenidate, Lisdexamfetamine) and non-stimulants (Atomoxetine).


3. Key Formulation Challenges for Psychotropics

Formulating these drugs is not straightforward because of their physical and chemical nature:

  1. High Lipophilicity (Fat-loving): Many psychotropics are designed to cross the fatty BBB. However, this means they are poorly soluble in water (aqueous solubility). If you can't dissolve a drug in water, you can't easily make a standard tablet or IV injection.

  2. Significant First-Pass Metabolism: When taken orally, the drug is absorbed from the gut and goes straight to the liver. The liver destroys a large portion of the drug (first-pass effect) before it reaches the brain. This makes plasma levels inconsistent.

  3. Narrow Therapeutic Index: This means the gap between a helpful dose and a toxic dose is very small. Lithium is a prime example—too little doesn't work, too much causes severe toxicity. Precise, stable formulations are required.

  4. Barriers to CNS Delivery: As mentioned, the Blood-Brain Barrier (BBB) restricts the entry of many drug molecules.

  5. Tolerance and Withdrawal: Long-term use of things like benzodiazepines can lead to tolerance (needing higher doses for the same effect) and severe withdrawal if stopped suddenly.


4. Physicochemical Properties Influencing Formulation

Formulators must evaluate the drug's physical properties:

  • Molecular Weight and Structure: Smaller molecules cross the BBB more easily. Larger molecules may need transporters.

  • pKa and Ionisation State: The pH of the gut and blood affects whether the drug is charged (ionised) or neutral. Neutral molecules cross cell membranes (and the BBB) more easily than charged ones.

  • Lipophilicity (LogP): A measure of how fat-soluble a drug is. Higher LogP = better membrane permeability, but lower water solubility. There is a "sweet spot" for CNS drugs.

  • Stability: Susceptibility to oxidation (oxygen damage), photodegradation (light damage), or moisture. This dictates how you must store and package the drug (e.g., in amber glass bottles).

  • Polymorphism: Some drugs can exist in different solid crystal forms (polymorphs). Even though the chemical formula is the same, different polymorphs can have different dissolution rates and bioavailability. Carbamazepine is a classic example—its polymorphs can affect how well the drug is absorbed.


5. The Blood-Brain Barrier (BBB)

The BBB is a highly selective border that protects the brain.

  • Tight Junctions: The endothelial cells lining the brain capillaries are welded together. Drugs cannot squeeze between the cells (paracellular diffusion).

  • Efflux Transporters (e.g., P-glycoprotein): These are like bouncers inside the cells. If a drug gets in, P-gp pumps it straight back out into the blood.

  • Selective Transport: Some nutrients (like amino acids) have specific doors (e.g., LAT1 transporter) to get in.

How formulation overcomes the BBB:

  • Prodrugs: Chemically altering the drug to make it more lipid-soluble so it slips through the membrane, then the body converts it back to the active drug.

  • Nanoparticles: Packaging the drug in tiny fat bubbles that cross the BBB.

  • Modifying Lipophilicity: Tweaking the chemical structure (e.g., adding a lipid tail) to enhance passive diffusion.


6. Conventional vs. New Delivery Systems

Conventional Formulations

  • Tablets, capsules, oral solutions: Most common. Cheap, convenient.

    • Pros: Flexible dosing.

    • Cons: First-pass metabolism, causing peak-trough fluctuations (blood levels spike high after a pill, causing side effects, then drop low before the next pill, causing symptom return), and adherence issues.

  • Parenteral (IV/IM) short-acting injections: Used for acute emergencies (e.g., severe agitation).

    • Pros: Rapid onset.

    • Cons: Painful, requires clinical supervision, formulation challenges (needs to be water-soluble and sterile).

New Delivery Systems (Advanced)

To fix the issues above, pharmacists developed:

  • Depot IM oil injections: Long-lasting shots.

  • Short-acting aqueous suspensions: Solid drug particles suspended in liquid for IM injection.

  • Extended-release solid dosage forms / capsules: Pills that slowly release the drug.

  • OROS (Osmotic controlled Release Oral delivery System): Used for methylphenidate (ADHD). Uses osmotic pressure to push the drug out of a tablet at a precise, slow rate.

  • Rapid-dissolving tablets: e.g., olanzapine, risperidone. Disintegrate in the mouth in seconds—useful for patients who hide pills or refuse to swallow.

  • Skin patches (Transdermal): Continuous absorption through the skin.


7. Long-Acting Injectable Antipsychotics (LAIs)

Also known as "depot" injections. These are crucial for psychiatry.

Why use them?

  • Adherence: Solves the problem of patients forgetting or choosing not to take daily pills.

  • Stable levels: Eliminates peak-trough fluctuations. The drug is released slowly and steadily into the blood.

  • Relapse prevention: Consistent drug levels keep symptoms at bay.

Common LAIs: Paliperidone palmitate, Risperidone microspheres, Aripiprazole, Flupentixol, Haloperidol decanoate.

Limitations:

  • Local injection site reactions (pain, swelling).

  • Long persistence: If a patient has a severe side effect, you cannot "take the pill back." The drug stays in their system for weeks or months.

  • Requires a trained nurse to administer deep into the muscle (gluteal or deltoid).


8. The Three Main LAI Technologies

How do we make a drug last for weeks or months?

  1. Oil-Based Depot Injections (e.g., Haloperidol decanoate):

    • The drug is attached to a long fatty acid chain (an ester) and dissolved in oil (e.g., sesame oil).

    • Once injected, tissue enzymes slowly break the ester bond (hydrolysis), releasing the active drug.

  2. PLGA Microsphere Depots (e.g., Risperidone Consta®):

    • The drug is encapsulated in microscopic spheres of a biodegradable polymer called PLGA (polylactic-co-glycolic acid).

    • The polymer slowly breaks down in the body via hydrolysis, releasing the drug over weeks.

  3. Nanocrystal Aqueous Suspensions (e.g., Paliperidone palmitate):

    • The drug is milled into tiny nanocrystals and suspended in water.

    • Because they are so small, they have a huge surface area, allowing for predictable slow dissolution and absorption.


9. Deep Dive: Depot Oil Formulations (Kinetics)

Let's look at how oil injections release drugs.

  • Oil Solutions: The drug is completely dissolved in the oil. It must partition (move) out of the oil into the surrounding body water to be absorbed.

  • Oil Suspensions: The drug is partly dissolved and partly suspended as solid particles. The solid particles act as a reservoir. As dissolved drug is absorbed, more solid drug dissolves to replace it.

The Math (Don't panic!)

1. Partition Coefficient (K):

K=CoCwK=Cw​Co​​

  • CoCo​ = Concentration of drug in oil.

  • CwCw​ = Concentration of drug in water.

  • Interpretation: A high K means the drug loves the oil and hates water. It will stay in the oil depot and release very slowly.

2. Fraction Available for Absorption (f):

f=(1−α)(1+Kα)f=(1+Kα)(1−α)​

  • ff = fraction of drug in the water (available to enter the blood).

  • αα = volume of oil / (volume of water + volume of oil).

  • Interpretation: If the drug is highly lipophilic (high K), the fraction in the water (ff) is tiny. This means absorption is very slow. By changing the formulation (e.g., using different oils or ester chain lengths), you can change K and control how fast the drug is released.


10. Depot Kinetics: The "Flip-Flop" Phenomenon

Normally, when you take a drug, it is absorbed fast, and the liver eliminates it slowly. The half-life is determined by the liver.

With a depot injection, it is the opposite:

  • The absorption from the oil depot into the blood is very slow.

  • The elimination by the liver is fast in comparison.

  • Therefore, the absorption rate becomes the "bottleneck" that controls the half-life. This is called "Flip-Flop" kinetics.

Example: Haloperidol

  • Oral tablet: Half-life ~1 day. Steady state in ~5 days. If you stop, the drug clears in a few days.

  • Haloperidol decanoate (Depot): The apparent half-life is ~3 weeks. It takes ~3 months to reach steady state. If you stop, the drug can persist for months.

Clinical consequences:

  • Overlap: You must give oral antipsychotics alongside the first depot injection for weeks until the depot reaches steady state.

  • Titration: If you change the depot dose, it takes months to see the full effect. Do not adjust too quickly.

  • Test Dose: Because it's impossible to remove the drug, you always give a small "test dose" first to check for severe allergic reactions.

  • Relapse: Symptoms may not return immediately after stopping, so follow-up must be long.


11. Case Study: Fluphenazine (Short vs. Long Esters)

Scenario: Fluphenazine comes in three forms:

  • Hydrochloride salt (C22): Short-acting.

  • Enanthate ester (C29): Medium-acting.

  • Decanoate ester (C32): Long-acting.

Compare and contrast:

  1. Partition Coefficient (o/w):

    • Decanoate (C32) has the longest carbon chain. This makes it the most lipophilic (fat-loving). It will have the highest o/w partition coefficient (K). It prefers to stay in the oil.

    • Enanthate (C29) is intermediate.

    • Hydrochloride (C22) is a salt, making it very water-soluble and minimally lipophilic. It has the lowest partition coefficient.

  2. Duration of Action:

    • Decanoate (C32): Highest K means it stays in the oil depot the longest. It partitions out very slowly. Duration: Longest (e.g., 2–4 weeks).

    • Enanthate (C29): Intermediate K. Duration: Medium (e.g., 1–2 weeks).

    • Hydrochloride (C22): Low K, dissolves rapidly in body water. Duration: Short (e.g., hours to days).


12. Deep Dive: Risperdal® Consta® (PLGA Microspheres)

This was the first long-acting injectable atypical antipsychotic. It uses a different technology than oil.

  • Formulation: It is a powder of microspheres. Risperidone is trapped inside a polymer matrix called PLGA (polylactide-co-glycolide) at a 75:25 ratio.

  • How it works: After deep IM injection, the PLGA polymer slowly breaks down (hydrolyses) in the body. As the polymer erodes, the risperidone is gradually released.

  • The "Lag Phase": Because the polymer takes time to start breaking down, there is a lag phase of about 3 weeks before significant drug release begins.

  • Clinical consequence: The patient must take oral risperidone (or another oral antipsychotic) for the first 3 weeks of treatment to prevent relapse.

  • Preparation: The microspheres are shipped as a dry powder. Right before injection, they must be suspended in a specific liquid (diluent) provided in the kit.


13. Glossary of Key Terms

Term

Definition

Adherence

The extent to which a patient takes their medication as prescribed.

Bioavailability

The proportion of a drug that enters the bloodstream and can have an active effect.

Blood-Brain Barrier (BBB)

A protective filter of tightly packed cells that stops harmful substances in the blood from reaching the brain.

Depot Injection

A long-acting injection that releases a drug slowly over time from a reservoir in the body.

Ester

A chemical compound formed by combining an acid and an alcohol. In prodrugs, esterifying a drug makes it more lipophilic.

First-Pass Metabolism

The destruction of a drug by the liver before it reaches the rest of the body, occurring after oral administration.

Flip-Flop Kinetics

When the absorption of a drug is slower than its elimination, making the absorption rate the determining factor for the drug's half-life.

Half-life

The time it takes for the concentration of a drug in the body to decrease by half.

Hydrolysis

The chemical breakdown of a compound due to reaction with water.

Lipophilicity

The ability of a molecule to dissolve in fats, oils, or lipids.

LogP

A measure of lipophilicity. Higher LogP = more lipophilic.

Microsphere

A tiny spherical particle (often made of polymer) used to encapsulate a drug for controlled release.

OROS

Osmotic controlled Release Oral delivery System. A tablet technology that pushes the drug out slowly using osmosis.

P-glycoprotein (P-gp)

An efflux transporter in the BBB that pumps drugs out of the brain back into the blood.

Partition Coefficient (K)

A measure of a drug's preference for an oil phase versus a water phase.

PLGA

Poly(lactic-co-glycolic acid). A biodegradable polymer used to make drug delivery microspheres.

Polymorphism

The ability of a solid material to exist in more than one crystal structure. Different forms can dissolve at different rates.

Prodrug

An inactive compound that is metabolized in the body to produce an active drug.

Therapeutic Index

The ratio between the toxic dose and the therapeutic dose of a drug. A narrow index means there is little margin for error.


14. Revision Questions

  1. Why is high lipophilicity a "double-edged sword" for psychotropic drugs?

  2. Explain the three main barriers of the Blood-Brain Barrier (BBB) and how formulation can overcome them.

  3. What is first-pass metabolism, and how does it affect oral psychotropics?

  4. Explain what a "peak-trough fluctuation" is and why it is a problem.

  5. Describe the three main technologies used for Long-Acting Injectable antipsychotics (LAIs).

  6. Explain the concept of "flip-flop" kinetics in relation to depot injections.

  7. Why must a patient take oral antipsychotics for 3 weeks after their first Risperdal Consta injection?

  8. In the Fluphenazine case study, why does the decanoate form last longer than the hydrochloride form?

  9. What is polymorphism, and why does it matter for carbamazepine?

  10. What are the advantages and disadvantages of depot injections compared to oral tablets?